Biophytis

Phase 3

Paris, FranceFounded 2006biophytis.com

Biophytis is a clinical-stage biotech focused on geroscience, aiming to treat age-related diseases by targeting the hallmarks of aging. Its core strategy revolves around three pillars: a proprietary AI-accelerated longevity research platform, the advanced Phase 3-ready program BIO101 for sarcopenia, and a parallel program for BIO101 in obesity as a combination therapy with GLP-1 agonists. The company has secured strategic partnerships and funding to advance its pipeline, including a landmark joint venture in Asia and an expanded AI collaboration with LynxKite.

Founded

2006

Focus

Small Molecules

AI Company Overview

Technology Platform

A unique longevity research platform that combines multiple technology modalities (target ID, screening, lead optimization) systematically accelerated by artificial intelligence (AI) through a partnership with LynxKite, focusing on the hallmarks of aging.

Funding History

Total raised: $44.5M

PIPE$5MUndisclosedOct 15, 2022

IPO$12MUndisclosedFeb 5, 2021

Series B$15MUndisclosedJun 15, 2017

Series A$10MUndisclosedJun 15, 2015

Opportunities

Biophytis has a first-mover opportunity to launch the first approved drug for sarcopenia, a vast and untreated market.

The obesity program positions BIO101 as a potential standard-of-care complement to blockbuster GLP-1 drugs, tapping into a multi-billion dollar market.

Its AI platform could generate a sustainable pipeline of novel longevity therapeutics across multiple indications.

Risk Factors

The company faces high clinical risk with its pivotal Phase 3 trial in an indication with no regulatory precedent.

It is financially dependent on raising additional capital to reach commercialization.

Significant competition may emerge in both sarcopenia and the crowded obesity therapeutic space.

Competitive Landscape

In sarcopenia, Biophytis's BIO101 is the most advanced candidate with no approved drugs, giving it a first-mover advantage. In obesity, it avoids direct GLP-1 competition by targeting muscle preservation as a combination therapy. Its AI-driven discovery differentiates it through a focused, data-rich approach to aging biology, though it competes with larger, well-funded AI-drug discovery platforms.